Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Assets Average (2017 - 2025)

Spero Therapeutics' Assets Average history spans 9 years, with the latest figure at $61.5 million for Q4 2025.

  • For Q4 2025, Assets Average fell 49.9% year-over-year to $61.5 million; the TTM value through Dec 2025 reached $61.5 million, down 49.9%, while the annual FY2025 figure was $89.7 million, 38.74% down from the prior year.
  • Assets Average reached $61.5 million in Q4 2025 per SPRO's latest filing, up from $58.1 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $175.0 million in Q1 2024 to a low of $58.1 million in Q3 2025.
  • Average Assets Average over 5 years is $117.3 million, with a median of $120.8 million recorded in 2023.
  • Peak YoY movement for Assets Average: soared 60.8% in 2023, then plummeted 59.2% in 2025.
  • A 5-year view of Assets Average shows it stood at $157.9 million in 2021, then crashed by 40.06% to $94.6 million in 2022, then soared by 52.94% to $144.7 million in 2023, then fell by 15.13% to $122.9 million in 2024, then plummeted by 49.9% to $61.5 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Assets Average are $61.5 million (Q4 2025), $58.1 million (Q3 2025), and $69.9 million (Q2 2025).